Click on headlines below to download research

Encouraging data for iPSCs opens potential
ReNeuron Group | 09/12/2022

ReNeuron Group has presented encouraging preclinical data surrounding the company’s conditionally immortalised induced pluripotent stem cell (CI…

Pushing on with CustomEx in H123
ReNeuron Group | 06/12/2022

With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k…

Rebranding in exosome targeted drug delivery
ReNeuron Group | 02/11/2022

ReNeuron is a UK-based stem cell research company now strategically re-focused on the development of its exosome drug delivery technologies. Recent encouraging…